Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo

Journal of Immunology

Volumn 182, Issue 1, 2009, Pages 371-378

  Bendrik, Christina ^a   Dabrosin, Charlotta ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY; PROGESTERONE; TAMOXIFEN; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BLOOD LEVEL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICRODIALYSIS; MOUSE; NONHUMAN; POSTMENOPAUSE; PREMENOPAUSE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REGULATORY MECHANISM; ADENOCARCINOMA; ANIMAL; BLOOD; BREAST TUMOR; CELL CULTURE; EXPERIMENTAL NEOPLASM; EXTRACELLULAR SPACE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NUDE MOUSE; PHYSIOLOGY; SECRETION; TUMOR CELL CULTURE; TUMOR CELL LINE; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; ESTRADIOL; EXTRACELLULAR SPACE; FEMALE; HUMANS; INTERLEUKIN-8; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 59849090487     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.1.371     Document Type: Article

References (49)

1. Collaborative Group on Hormonal Factors in Breast Cancer. 1997. Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047-1059.
2. Olsson, H. L., C. Ingvar, and A. Bladstrom. 2003. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 97: 1387-1392.
3. Rossouw, J. E., G. L. Anderson, R. L. Prentice, A. Z. LaCroix, C. Kooperberg, M. L. Stefanick, R. D. Jackson, S. A. Beresford, B. V. Howard, K. C. Johnson, et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288: 321-333.
4. Beral, V. 2003. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419-427.
5. Xie, K. 2001. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 12: 375-391.
6. Benoy, I. H., R. Salgado, P. Van Dam, K. Geboers, E. Van Marck, S. Scharpe, P. B. Vermeulen, and L. Y. Dirix. 2004. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 10: 7157-7162.
7. Smith, K. C., A. C. Bateman, H. M. Fussell, and W. M. Howell. 2004. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur. J. Immunogenet. 31: 167-173.
8. Miller, L. J., S. H. Kurtzman, Y. Wang, K. H. Anderson, R. R. Lindquist, and D. L. Kreutzer. 1998. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res. 18: 77-81.
9. De Larco, J. E., B. R. Wuertz, K. A. Rosner, S. A. Erickson, D. E. Gamache, J. C. Manivel, and L. T. Furcht. 2001. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am. J. Pathol. 158: 639-646.
10. Li, A., S. Dubey, M. L. Varney, B. J. Dave, and R. K. Singh. 2003. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol. 170: 3369-3376.
11. Salcedo, R., M. Martins-Green, B. Gertz, J. J. Oppenheim, and W. J. Murphy. 2002. Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts. Clin. Cancer Res. 8: 2655-2665.
12. Holmes, W. E., J. Lee, W. J. Kuang, G. C. Rice, and W. I. Wood. 1991. Structure and functional expression of a human interleukin-8 receptor. Science 253: 1278-1280.
13. Li, A., M. L. Varney, and R. K. Singh. 2001. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin. Cancer Res. 7: 3298-3304.
14. Freund, A., C. Chauveau, J. P. Brouillet, A. Lucas, M. Lacroix, A. Licznar, F. Vignon, and G. Lazennec. 2003. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22: 256-265.
15. Kanda, N., and S. Watanabe. 2001. 17β-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production. J. Invest. Dermatol. 117: 274-283.
16. Bengtsson, A. K., E. J. Ryan, D. Giordano, D. M. Magaletti, and E. A. Clark. 2004. 17β-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood 104: 1404-1410.
17. Lin, Y., R. Huang, L. Chen, S. Li, Q. Shi, C. Jordan, and R. P. Huang. 2004. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int. J. Cancer 109: 507-515.
18. Seeger, H., D. Wallwiener, and A. O. Mueck. 2005. Different effects of estradiol and various antiestrogens on TNF-α-induced changes of biochemical markers for growth and invasion of human breast cancer cells. Life Sci. 78: 1464-1468.
19. Azenshtein, E., T. Meshel, S. Shina, N. Barak, I. Keydar, and A. Ben-Baruch. 2005. The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. Cancer Lett. 217: 73-86.
20. Suzuki, T., and D. A. Sullivan. 2005. Estrogen stimulation of proinflammatory cytokine and matrix metalloproteinase gene expression in human corneal epithelial cells. Cornea 24: 1004-1009.
21. Akoum, A., C. Lawson, S. McColl, and M. Villeneuve. 2001. Ectopic endometrial cells express high concentrations of interleukin (IL)-8 in vivo regardless of the menstrual cycle phase and respond to oestradiol by up-regulating IL-1-induced IL-8 expression in vitro. Mol. Hum. Reprod. 7: 859-866.
22. Dabrosin, C. 2005. Microdialysis: an in vivo technique for studies of growth factors in breast cancer. Front. Biosci. 10: 1329-1335.
23. Garvin, S., U. W. Nilsson, F. R. Huss, G. Kratz, and C. Dabrosin. 2006. Estradiol increases VEGF in human breast studied by whole-tissue culture. Cell Tissue Res. 325: 245-251.
24. Dabrosin, C. 2001. Technical aspects of microdialysis of human breast. Scand. J. Clin. Lab. Invest. 61: 269-272.
25. Dabrosin, C. 2003. Variability of vascular endothelial growth factor in normal human breast tissue in vivo during the menstrual cycle. J. Clin. Endocrinol. Metab. 88: 2695-2698.
26. Dabrosin, C., A. Hallstrom, U. Ungerstedt, and M. Hammar. 1997. Microdialysis of human breast tissue during the menstrual cycle. Clin. Sci. 92: 493-496.
27. Dabrosin, C., K. Ollinger, U. Ungerstedt, and M. Hammar. 1997. Variability of glutathione levels in normal breast tissue and subcutaneous fat during the menstrual cycle: an in vivo study with microdialysis technique. J. Clin. Endocrinol. Metab. 82: 1382-1384.
28. Ungerstedt, U. 1991. Microdialysis-principles and applications for studies in animals and man. J. Intern. Med. 230: 365-373.
29. Rosdahl, H., K. Hamrin, U. Ungerstedt, and J. Henriksson. 1998. Metabolite levels in human skeletal muscle and adipose tissue studied with microdialysis at low perfusion flow. Am. J. Physiol. 274: E936-E945.
30. Schor, A. M., N. Pendleton, S. Pazouki, R. L. Smither, J. Morris, K. Lessan, E. Heerkens, L. M. Chandrachud, G. Carmichael, M. Adi, D. M. Chisholm, and H. Stevenson. 1998. Assessment of vascularity in histological sections: effects of methodology and value as an index of angiogenesis in breast tumours. Histochem. J. 30: 849-856.
31. Jaffe, E. A., R. L. Nachman, C. G. Becker, and C. R. Minick. 1973. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J. Clin. Invest. 52: 2745-2756.
32. Koch, A. E., P. J. Polverini, S. L. Kunkel, L. A. Harlow, L. A. DiPietro, V. M. Elner, S. G. Elner, and R. M. Strieter. 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798-1801.
33. Green, A. R., V. L. Green, M. C. White, and V. Speirs. 1997. Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identi-fication of interleukin-8 as a potential regulatory factor in breast tumours. Int. J. Cancer 72: 937-941.
34. Yokoe, T., Y. Iino, H. Takei, J. Horiguchi, Y. Koibuchi, M. Maemura, S. Ohwada, and Y. Morishita. 1997. Changes of cytokines and thyroid function in patients with recurrent breast cancer. Anticancer Res. 17: 695-699.
35. Arenberg, D. A., S. L. Kunkel, P. J. Polverini, M. Glass, M. D. Burdick, and R. M. Strieter. 1996. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 97: 2792-2802.
36. Heidemann, J., H. Ogawa, M. B. Dwinell, P. Rafiee, C. Maaser, H. R. Gockel, M. F. Otterson, D. M. Ota, N. Lugering, W. Domschke, and D. G. Binion. 2003. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. 278: 8508-8515.
37. Dabrosin, C. 2005. Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. Clin. Cancer Res. 11: 8036-8041.
38. Dabrosin, C., P. J. Margetts, and J. Gauldie. 2003. Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. Int. J. Cancer 107: 535-540.
39. Dabrosin, C., K. Palmer, W. J. Muller, and J. Gauldie. 2003. Estradiol promotes growth and angiogenesis in polyoma middle T transgenic mouse mammary tumor explants. Breast Cancer Res. Treat. 78: 1-6.
40. Garvin, S., and C. Dabrosin. 2003. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res. 63: 8742-8748.
41. Garvin, S., U. W. Nilsson, and C. Dabrosin. 2005. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br. J. Cancer 93: 1005-1010.
42. Queen, M. M., R. E. Ryan, R. G. Holzer, C. R. Keller-Peck, and C. L. Jorcyk. 2005. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res. 65: 8896-8904.
43. Ravdin, P. M., S. Green, T. M. Dorr, W. L. McGuire, C. Fabian, R. P. Pugh, R. D. Carter, S. E. Rivkin, J. R. Borst, R. J. Belt, et al. 1992. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol. 10: 1284-1291.
44. Horwitz, K. B., Y. Koseki, and W. L. McGuire. 1978. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103: 1742-1751.
45. Hulka, B. S., and A. T. Stark. 1995. Breast cancer: cause and prevention. Lancet 346: 883-887.
46. Pike, M. C., C. L. Pearce, and A. H. Wu. 2004. Prevention of cancers of the breast, endometrium and ovary. Oncogene 23: 6379-6391.
47. Early Breast Cancer Trialists' Collaborative Group. 1998. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467.
48. Fisher, B., J. P. Costantino, D. L. Wickerham, C. K. Redmond, M. Kavanah, W. M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, et al. 1998. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90: 1371-1388.
49. Howell, A., J. Cuzick, M. Baum, A. Buzdar, M. Dowsett, J. F. Forbes, G. Hoctin-Boes, J. Houghton, G. Y. Locker, and J. S. Tobias. 2005. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62.